Nexeon Medsystems (NXNN) Rating Increased to Hold at Zacks Investment Research
Nexeon Medsystems (OTCMKTS:NXNN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, May 29th.
According to Zacks, “Nexeon MedSystems, Inc. is a medical device company. It focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases. Nexeon MedSystems, Inc. is based in DALLAS, United States. “
Separately, ValuEngine upgraded Nexeon Medsystems from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
Nexeon Medsystems (OTCMKTS:NXNN) last posted its quarterly earnings results on Monday, May 21st. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.03. The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $1.70 million. analysts predict that Nexeon Medsystems will post -0.23 earnings per share for the current year.
Nexeon Medsystems Company Profile
Nexeon MedSystems Inc, a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.